Ashton Thomas Private Wealth, LLC
Position in LGND — Ligand Pharmaceuticals Inc
CIK 2019663
SCOTTSDALE, AZ
Position in LGND
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$438,032
+$40,418 QoQ
Shares Held
2,194
+4.3% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ashton Thomas Private Wealth, LLC holds $8,478,289 across 12 Biotechnology names. LGND ranks #6 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
33,597 | $3,162,149 | |
| 2 | EXEL |
Exelixis, Inc.
|
26,638 | $1,142,503 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,556 | $1,141,356 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
15,234 | $984,573 | |
| 5 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
38,292 | $948,109 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
This page
|
2,194 | $438,032 | |
| 7 | ARGX |
Argenx SE
|
284 | $207,391 | |
| 8 | NAUT |
Nautilus Biotechnology, Inc.
|
45,000 | $174,600 |
All Filings in LGND
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $438,032 | 2,194 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $397,614 | 2,103 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $356,759 | 2,014 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $222,585 | 1,958 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $208,492 | 1,983 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $208,621 | 1,947 | Shares | Sole | 2025-02-07 | |
| 2024-06-30 | $159,335 | 1,891 | Shares | Sole | 2024-08-07 | |
| No filing history on record for this holder in this stock. | ||||||